2018 Press Releases

Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014
DateTitle 
06/18/18INSYS Therapeutics Provides an Update on Its Ongoing Transformation
PHOENIX, June 18, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today reiterated its ongoing efforts to fundamentally transform the company. Below is a synopsis of these ongoing efforts. New Governance, New Employee Base, New Vision and Culture President and Chief Executive Officer Saeed Motahari joined INSYS in April 2017. Since then: Two-thirds of ... 
Printer Friendly Version
06/14/18Epinephrine Nasal Spray in Development for Treatment of Anaphylaxis Shows Promise as Potential Alternative to Intramuscular Injection
PHOENIX, June 14, 2018 (GLOBE NEWSWIRE) -- Allergy sufferers who experience anaphylaxis—an acute, life-threatening allergic reaction requiring urgent treatment—may soon have a new delivery option for receiving a timely dose of epinephrine to avoid a potentially fatal outcome. INSYS Therapeutics, Inc. (NASDAQ:INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, announced today that its investigational epinephrine nasal spr... 
Printer Friendly Version
06/04/18INSYS Therapeutics to Present at Jefferies Global Healthcare Conference
PHOENIX, June 04, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, announced today that Saeed Motahari, president and chief executive officer, and Andy Long, chief financial officer, will present at the upcoming Jefferies 2018 Global Healthcare Conference as follows: Date: Friday, June 8, 2018 Time:  9:30 a.m. Eastern Time ... 
Printer Friendly Version
05/22/18INSYS Therapeutics Confirms Outcome of FDA Advisory Committee Meeting on Buprenorphine Sublingual Spray
PHOENIX, May 22, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, confirmed today that an expert panel convened by the U.S. Food and Drug Administration (FDA) voted not to recommend approval of the company’s New Drug Application (NDA) for a buprenorphine sublingual spray as a treatment for moderate-to-severe acute pain. “We appreciate the panelists’ perspective... 
Printer Friendly Version
05/15/18INSYS Therapeutics Responds to Unsealing of Previously Filed Qui Tam Complaints and Recaps Transformation Efforts
PHOENIX, May 15, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today issued the following response to the unsealing of the previously filed Qui Tam complaints and the public release of the intervention of the Department of Justice (DOJ) in such cases: In December 2013, INSYS received a subpoena from the Office of Inspector General (OIG) of the Department of He... 
Printer Friendly Version
05/08/18INSYS Therapeutics Announces Exclusive License Partnership with Lunatus to Commercialize SUBSYS® (fentanyl sublingual spray) in the Middle East
PHOENIX, May 08, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, announced today that it has agreed to an exclusive license partnership with Lunatus for commercialization of SUBSYS® (fentanyl sublingual spray) in the Middle East. Based in Dubai with satellite offices across the Gulf Cooperation Council, Lunatus will be the exclusive licensee for SUBSYS® in Bah... 
Printer Friendly Version
05/08/18INSYS Therapeutics Reports First Quarter 2018 Results
Cannabinoid and spray-technology focused pipeline continues to advance, while efforts to stabilize SUBSYS® revenue continue PHOENIX, May 08, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today reported financial results for its first quarter ended March 31, 2018. OVERALL HIGHLIGHTS Achieved gross revenue in first quarter of $38.5 million, down 26% ve... 
Printer Friendly Version
04/27/18INSYS Therapeutics Initiates Phase 2 Clinical Trial of Cannabidiol (CBD) for Treatment of Prader-Willi Syndrome
Study will evaluate safety and efficacy of company’s CBD product candidate in rare genetic disease characterized by insatiable appetite in children PHOENIX, April 27, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, recently initiated a Phase 2 clinical trial of its cannabidiol (CBD) oral solution for evaluation of safety and efficacy in pediatric patients with P... 
Printer Friendly Version
04/26/18INSYS Therapeutics and University of California (UC) San Diego Center for Medicinal Cannabis Research to Collaborate on Clinical Trial
Company’s pharmaceutical-grade cannabidiol (CBD) oral solution will be evaluated by UC San Diego/CMCR researchers as potential treatment for symptoms of autism PHOENIX, April 26, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced a collaboration with the University of California (UC) San Diego School of Medicine’s Center for Medicinal Cannabis Resea... 
Printer Friendly Version
04/25/18INSYS Therapeutics to Report First Quarter 2018 Results on May 8
PHOENIX, April 25, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced that it will release its first quarter 2018 financial results on Tuesday, May 8, after the U.S. financial markets close. Following the release, Saeed Motahari, president and chief executive officer, and Andrew Long, chief financial officer, will host a conference call at 5:00 p.... 
Printer Friendly Version
04/18/18INSYS Therapeutics to Advance Clinical Research of Dronabinol Inhalation Using Novel Breath-Actuated Device
PHOENIX, April 18, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced plans to advance clinical research of dronabinol inhalation using a novel and patented breath-actuated device—licensed from U.K.-based Senzer Ltd. and accepted by the U.S. Food and Drug Administration (FDA) under an investigational new drug (IND) filing—in the second half of 2018. ... 
Printer Friendly Version
04/02/18INSYS Therapeutics Appoints Trudy Vanhove to Board of Directors
PHOENIX, April 02, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced the appointment of Trudy Vanhove as a new independent member of its Board of Directors. Given her extensive experience in clinical development and medical affairs, Dr. Vanhove will also serve on the Board’s R&D committee. “Trudy’s deep understanding and knowledge of pharmaceutic... 
Printer Friendly Version
03/19/18INSYS Therapeutics Reiterates Commitment to Compliant and Ethical Business Practices and Advancing Innovative Product Pipeline
PHOENIX, March 19, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today released the following statement: The company continues striving to take responsibility for inappropriate actions of some former employees and has invested significant resources over the last several years to establish an effective compliance program and build an organizational culture of... 
Printer Friendly Version
03/08/18INSYS Therapeutics Reports Fourth Quarter and Full Year 2017 Results
Foundation to become global leader in pharmaceutical cannabinoids and spray technology established in 2017 through new leadership and acceleration of product pipeline PHOENIX, March 08, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today reported financial results for its fourth quarter and full year ended Dec. 31, 2017. OVERALL HIGHLIGHTS Achieved gro... 
Printer Friendly Version
03/02/18INSYS Therapeutics Initiates Phase 3 Clinical Trial of Cannabidiol (CBD) Oral Solution for Treatment of Infantile Spasms
Pivotal study aims to evaluate safety and efficacy of company’s novel CBD product candidate in rare type of pediatric epilepsy PHOENIX, March 02, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced the initiation of a Phase 3 clinical trial to study cannabidiol (CBD) oral solution for the treatment of infantile spasms, a rare type of pediatric epilep... 
Printer Friendly Version
03/01/18INSYS Therapeutics Confirms Completion of Founder’s Independent Trust
PHOENIX, March 01, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced that company founder John N. Kapoor, Ph.D., has completed the previously announced formation of an independently controlled trust related to his ownership stake in the company. The trust has been publicly filed with the Securities and Exchange Commission by the company on a Curren... 
Printer Friendly Version
02/23/18INSYS Therapeutics to Report Fourth Quarter 2017 Results on March 8
PHOENIX, Feb. 23, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced that it will release its fourth quarter and full year 2017 financial results on Thursday, March 8, after the U.S. financial markets close. Following the release, Saeed Motahari, president and chief executive officer, and Andrew Long, chief financial officer, will host a conferenc... 
Printer Friendly Version
02/20/18INSYS Therapeutics to Present at RBC Healthcare Conference
PHOENIX, Feb. 20, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, announced today that Saeed Motahari, president and chief executive officer, and Andrew Long, chief financial officer, will present at the RBC Capital Markets Global Healthcare Conference as follows: Date:  Thursday, Feb. 22, 2018   Time: 10:00 a.m. Eastern S... 
Printer Friendly Version
02/09/18INSYS Therapeutics Addresses Maryland Attorney General’s Motion
PHOENIX, Feb. 09, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today released the following statement in response to a motion filed by the Office of the Maryland Attorney General: Consistent with our management team’s sincere commitment to conduct business according to high ethical standards and the best interests of patients, ... 
Printer Friendly Version
02/01/18INSYS Therapeutics Addresses New York Attorney General’s Complaint
PHOENIX, Feb. 01, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today released the following statement in response to a complaint filed by the New York attorney general: Like so many stakeholders in the healthcare community and in the government, we share the desire to address the serious national challenge related to the misuse and abuse of opioids that has... 
Printer Friendly Version
02/01/18INSYS Therapeutics Appoints Vaseem Mahboob to Board of Directors
PHOENIX, Feb. 01, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced the appointment of Vaseem Mahboob as a new independent member of its board of directors. A former GE Healthcare finance executive and the current chief financial officer of Endologix, Inc., Mr. Mahboob will also serve on the board’s audit committee. “Vaseem brings a breadth and d... 
Printer Friendly Version
01/30/18INSYS Therapeutics Adds Two New Executives to Senior Management Team
VP of Human Resources, Carol Summersgill; VP of Clinical Development, Dr. Ahmed Elkashef PHOENIX, Jan. 30, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced the addition of two new executives to its senior management team: Carol L. Summersgill as vice president of human resources Ahmed Elkashef, M.D., as vice president of clinical develo... 
Printer Friendly Version
01/03/18INSYS Therapeutics to Present at J.P. Morgan Healthcare Conference
PHOENIX, Jan. 03, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY), announced today that Saeed Motahari, president and chief executive officer, and Andrew Long, chief financial officer, will present at the 36th annual J.P. Morgan Healthcare Conference as follows: Date:       Thursday, Jan. 11, 2018 Time:       7:30 a.m. Pacific Standard Time Location:       San Francisco – Westin S... 
Printer Friendly Version